Lishengpharma: Potassium Chloride Sustained-Release Tablets have passed the market approval application
Lishengpharma announced that the company has obtained the drug registration certificates for potassium chloride sustained-release tablets in specifications of 0.5g and 0.6g issued by the National Medical Products Administration, marking the approval of the drug for market licensing application. This drug is suitable for the treatment and prevention of hypokalemia, especially in cases where dietary management or reduced diuretic treatment is ineffective
According to the Zhitong Finance APP, Lishengpharma (002393.SZ) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the 0.5g specification of potassium chloride sustained-release tablets; and the "Drug Registration Certificate" for the 0.6g specification of potassium chloride sustained-release tablets. The above-mentioned drugs have passed the drug marketing license application.
The indications for potassium chloride sustained-release tablets are: for the treatment and prevention of hypokalemia with or without metabolic alkalosis, when dietary management with potassium-rich foods or reducing the dosage of diuretics is ineffective in these patients
